Multiple biomarkers for the prediction of first major cardiovascular events and death.
暂无分享,去创建一个
D. Levy | R. D'Agostino | E. Benjamin | R. Vasan | Thomas J. Wang | C. Newton-Cheh | Philimon N. Gona | N. Rifai | M. Larson | G. Tofler | S. Robins | P. Jacques | J. Selhub | D. Levy | P. Gona | C. Newton‐Cheh
[1] B. Gersh. Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death , 2008 .
[2] J. Ware. The limitations of risk factors as prognostic tools. , 2006, The New England journal of medicine.
[3] S. Yusuf,et al. Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study , 2006, Circulation.
[4] Eric Boerwinkle,et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. , 2006, Archives of internal medicine.
[5] M. Pencina,et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. , 2005, Archives of internal medicine.
[6] P. Greenland,et al. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. , 2005, Archives of internal medicine.
[7] H Tunstall-Pedoe,et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.
[8] B. Howard,et al. C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of Diabetes: The Strong Heart Study , 2005, Circulation.
[9] J. Polak,et al. C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study , 2005, Circulation.
[10] P. Hildebrandt,et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. , 2005, JAMA.
[11] L. Køber,et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. , 2005, The New England journal of medicine.
[12] C. Meisinger,et al. Lipoprotein-Associated Phospholipase A2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population: Results From the 14-Year Follow-Up of a Large Cohort From Southern Germany , 2004, Circulation.
[13] M. Pencina,et al. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation , 2004, Statistics in medicine.
[14] P. Ridker,et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. , 2004, Circulation.
[15] M. Pepe,et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. , 2004, American journal of epidemiology.
[16] Vilmundur Gudnason,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.
[17] J. Geleijnse,et al. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk , 2004, Thrombosis and Haemostasis.
[18] Daniel Levy,et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.
[19] A. Dyer,et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. , 2003, JAMA.
[20] S. Haffner,et al. Inflammation in the Prediabetic State Is Related to Increased Insulin Resistance Rather Than Decreased Insulin Secretion , 2003, Circulation.
[21] A. Dyer,et al. Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events , 2003 .
[22] Eric J Topol,et al. Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.
[23] S. Cummings,et al. The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. , 2003, The American journal of medicine.
[24] Gary L Myers,et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.
[25] A. Mangoni,et al. Homocysteine and cardiovascular disease: current evidence and future prospects. , 2002, The American journal of medicine.
[26] Ose,et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .
[27] R. Beaglehole,et al. The real contribution of the major risk factors to the coronary epidemics: time to end the "only-50%" myth. , 2001, Archives of internal medicine.
[28] S. Yusuf,et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.
[29] S. Vollset,et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. , 2001, The American journal of clinical nutrition.
[30] J. Danesh,et al. Fibrin D-Dimer and Coronary Heart Disease: Prospective Study and Meta-Analysis , 2001, Circulation.
[31] L. Bouter,et al. Follow-Up of the Hoorn Study Hyperhomocysteinemia Increases Risk of Death , Especially in Type 2 Diabetes : 5-Year , 2000 .
[32] H. Cohen,et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.
[33] A. Sharrett,et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[34] L. Weinehall,et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. , 1998, Circulation.
[35] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[36] S. Vollset,et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. , 1997, The New England journal of medicine.
[37] J. Laragh,et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. , 1997, American journal of hypertension.
[38] J. Laragh,et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. , 1991, The New England journal of medicine.
[39] S. Rahimtoola,et al. Impaired fibrinolysis in coronary artery disease. , 1988, American heart journal.
[40] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[41] D.,et al. Regression Models and Life-Tables , 2022 .